Knight Therapeutics (TSE:GUD) Reaches New 1-Year High – Here’s Why

Knight Therapeutics Inc. (TSE:GUD)’s share price reached a new 52-week high on Monday . The stock traded as high as C$7.56 and last traded at C$7.48, with a volume of 15167 shares traded. The stock had previously closed at C$7.45.

Knight Therapeutics Stock Performance

The company’s 50-day simple moving average is C$6.43 and its 200 day simple moving average is C$6.12. The company has a current ratio of 2.39, a quick ratio of 1.79 and a debt-to-equity ratio of 10.15. The stock has a market cap of C$749.97 million, a P/E ratio of -153.00, a PEG ratio of -1,013.50 and a beta of -0.29.

Knight Therapeutics (TSE:GUD) last posted its earnings results on Thursday, March 19th. The company reported C$0.09 EPS for the quarter. Knight Therapeutics had a negative net margin of 1.19% and a negative return on equity of 0.70%. The firm had revenue of C$133.20 million for the quarter. As a group, sell-side analysts expect that Knight Therapeutics Inc. will post 0.1009486 EPS for the current fiscal year.

About Knight Therapeutics

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.